Monica M. Purmalek

Monica M. Purmalek

Auto-generated profile, based on publicly available information

Monica M. Purmalek

National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, Maryland

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 January 2016 in Nature Medicine
Verified
Journal Article
Open access
PDF file
CLChristian Lood
Christian Lood
LBLuz P Blanco
Luz P Blanco
MPMonica M Purmalek
Monica M Purmalek
CCCarmelo Carmona-Rivera
Carmelo Carmona-Rivera
SRSuk S De Ravin
Suk S De Ravin
MKMariana J Kaplan
Mariana J Kaplan
Lupus-like disease is driven by NETs enriched in mitochondrial DNA. Neutrophil extracellular traps (NETs) are implicated in autoimmunity, but how they are generated and their roles in sterile inflammation remain unclear. Ribonucleoprotein immune complexes (RNP ICs), inducers of NETosis, require mitochondrial reactive oxygen species (ROS) for maximal NET stimulation. After RNP IC stimulation of neutrophils, mitochondria become hypopolarized and translocate to the cell surface. Extracellular release of oxidized mitochondrial DNA is proinflammatory in vitro, and when this DNA is injected into mice, it stimulates type I interferon (IFN) signaling through a pathway dependent on the DNA sensor STING. Mitochondrial ROS are also necessary for spontaneous NETosis of low-density granulocytes from individuals with systemic lupus erythematosus. This was also observed in individuals with chronic granulomatous disease, who lack NADPH oxidase activity but still develop autoimmunity and type I IFN signatures. Mitochondrial ROS inhibition in vivo reduces disease severity and type I IFN responses in a mouse model of lupus. Together, these findings highlight a role for mitochondria in the generation not only of NETs but also of pro-inflammatory oxidized mitochondrial DNA in autoimmune diseases.

13 February 2020 in JCI Insight
Verified
Journal Article
Open access
PDF file
NSNickie Seto
Nickie Seto
JTJose Jiram Torres-Ruiz
Jose Jiram Torres-Ruiz
CCCarmelo Carmona-Rivera
Carmelo Carmona-Rivera
IPIago Pinal-Fernandez
Iago Pinal-Fernandez
KPKatherine Pak
Katherine Pak
MKMariana J. Kaplan
Mariana J. Kaplan
Idiopathic inflammatory myopathies (IIM) are characterized by muscle inflammation and weakness, myositis-specific autoantibodies (MSAs), and extramuscular organ damage. The role of neutrophil dysregulation and neutrophil extracellular traps (NETs) in IIM is unclear. We assessed whether pathogenic neutrophil subsets (low-density granulocytes [LDGs]) and NETs were elevated in IIM, associated with clinical presentation and MSAs, and their effect on skeletal myoblasts and myotubes. Circulating NETs and LDGs were quantified and correlated with clinical measures. Specific MSAs were tested for their ability to induce NETs. NETs and neutrophil gene expression were measured in IIM biopsies. Whether NETs damage skeletal myoblasts and myotubes was tested. Circulating LDGs and NETs were increased in IIM. IIM LDGs had an enhanced ability to form NETs. LDGs and NETs correlated with IIM disease activity and muscle damage. The serum MSA anti-MDA5 correlated with circulating and tissue NETs and directly enhanced NET formation. An enhanced neutrophil gene signature was present in IIM muscle and associated with muscle injury and tissue IFN gene signatures. IIM NETs decreased the viability of myotubes in a citrullinated histone-dependent manner. Dysregulated neutrophil pathways may play pathogenic roles in IIM through their ability to directly injure muscle cells and other affected tissues.

9 February 2017 in Arthritis & Rheumatology
Verified
Journal Article
Closed access
PDF file
MDM. Kristen Demoruelle
M. Kristen Demoruelle
KHKylie K. Harrall
Kylie K. Harrall
LHLinh Ho
Linh Ho
MPMonica M. Purmalek
Monica M. Purmalek
NSNickie L. Seto
Nickie L. Seto
KDKevin D. Deane
Kevin D. Deane

6 March 2017 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
MFMohd Hafeez Faridi
Mohd Hafeez Faridi
SKSamia Q. Khan
Samia Q. Khan
WZWenpu Zhao
Wenpu Zhao
HLHa Won Lee
Ha Won Lee
MAMehmet Mete Altintas
Mehmet Mete Altintas
VGVineet Gupta
Vineet Gupta
Genetic variations in the ITGAM gene (encoding CD11b) strongly associate with risk for systemic lupus erythematosus (SLE). Here we have shown that 3 nonsynonymous ITGAM variants that produce defective CD11b associate with elevated levels of type I interferon (IFN-I) in lupus, suggesting a direct link between reduced CD11b activity and the chronically increased inflammatory status in patients. Treatment with the small-molecule CD11b agonist LA1 led to partial integrin activation, reduced IFN-I responses in WT but not CD11b-deficient mice, and protected lupus-prone MRL/Lpr mice from end-organ injury. CD11b activation reduced TLR-dependent proinflammatory signaling in leukocytes and suppressed IFN-I signaling via an AKT/FOXO3/IFN regulatory factor 3/7 pathway. TLR-stimulated macrophages from CD11B SNP carriers showed increased basal expression of IFN regulatory factor 7 (IRF7) and IFN-β, as well as increased nuclear exclusion of FOXO3, which was suppressed by LA1-dependent activation of CD11b. This suggests that pharmacologic activation of CD11b could be a potential mechanism for developing SLE therapeutics.

2 March 2018 in Arthritis & Rheumatology
Verified
Journal Article
Closed access
PDF file
MDM. Kristen Demoruelle
M. Kristen Demoruelle
EBEmily Bowers
Emily Bowers
LLLauren J. Lahey
Lauren J. Lahey
JSJeremy Sokolove
Jeremy Sokolove
MPMonica Purmalek
Monica Purmalek
KDKevin D. Deane
Kevin D. Deane

9 February 2017 in JCI Insight
Verified
Journal Article
Open access
PDF file
CCCarmelo Carmona-Rivera
Carmelo Carmona-Rivera
MPMonica M. Purmalek
Monica M. Purmalek
EMErica Moore
Erica Moore
MWMeryl Waldman
Meryl Waldman
PWPeter J. Walter
Peter J. Walter
PGPeter C. Grayson
Peter C. Grayson
Levamisole, an anthelmintic drug with cholinergic properties, has been implicated in cases of drug-induced vasculitis when added to cocaine for profit purposes. Neutrophil extracellular trap (NET) formation is a cell death mechanism characterized by extrusion of chromatin decorated with granule proteins. Aberrant NET formation and degradation have been implicated in idiopathic autoimmune diseases that share features with levamisole-induced autoimmunity as well as in drug-induced autoimmunity. This study’s objective was to determine how levamisole modulates neutrophil biology and its putative effects on the vasculature. Murine and human neutrophils exposed to levamisole demonstrated enhanced NET formation through engagement of muscarinic subtype 3 receptor. Levamisole-induced NETosis required activation of Akt and the RAF/MEK/ERK pathway, ROS induction through the nicotinamide adenine dinucleotide phosphate oxidase, and peptidylarginine deiminase activation. Sera from two cohorts of patients actively using levamisole-adulterated cocaine displayed autoantibodies against NET components. Cutaneous biopsy material obtained from individuals exposed to levamisole suggests that neutrophils produce NETs in areas of vasculitic inflammation and thrombosis. NETs generated by levamisole were toxic to endothelial cells and impaired endothelium-dependent vasorelaxation. Stimulation of muscarinic receptors on neutrophils by cholinergic agonists may contribute to the pathophysiology observed in drug-induced autoimmunity through the induction of inflammatory responses and neutrophil-induced vascular damage.